3. GOOD HEALTH AND WELL-BEING

DexCom, Inc. (NASDAQ:DXCM) Stake Lifted by Truist Financial Corp – Defense World

Written by Amanda

DexCom, Inc. (NASDAQ:DXCM) Stake Lifted by Truist Financial Corp  Defense World

Truist Financial Corp increased its stake in DexCom, Inc. (NASDAQ:DXCMGet Rating) by 21.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,344 shares of the medical device company’s stock after acquiring an additional 4,940 shares during the period. Truist Financial Corp’s holdings in DexCom were worth $14,502,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of DXCM. Capital Research Global Investors boosted its holdings in shares of DexCom by 55.2% in the fourth quarter. Capital Research Global Investors now owns 2,374,545 shares of the medical device company’s stock valued at $1,275,020,000 after acquiring an additional 844,916 shares in the last quarter. Norges Bank bought a new stake in DexCom during the fourth quarter worth approximately $410,670,000. Allspring Global Investments Holdings LLC bought a new stake in DexCom during the fourth quarter worth approximately $263,141,000. Ownership Capital B.V. boosted its holdings in DexCom by 49.8% during the fourth quarter. Ownership Capital B.V. now owns 460,628 shares of the medical device company’s stock worth $247,334,000 after buying an additional 153,233 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new stake in DexCom during the fourth quarter worth approximately $75,142,000. Institutional investors and hedge funds own 93.26% of the company’s stock.

A number of analysts recently weighed in on DXCM shares. Piper Sandler reduced their target price on shares of DexCom from $181.25 to $120.00 in a report on Friday, April 29th. StockNews.com assumed coverage on shares of DexCom in a report on Thursday, March 31st. They set a “hold” rating for the company. Raymond James reduced their price target on shares of DexCom from $134.50 to $121.50 in a research report on Friday, April 29th. Citigroup lowered their price objective on shares of DexCom from $157.50 to $131.25 and set a “buy” rating on the stock in a research report on Tuesday, May 17th. Finally, Morgan Stanley lowered their price objective on shares of DexCom to $90.75 and set an “equal weight” rating on the stock in a research report on Monday, June 13th. Two research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $132.75.

In related news, EVP Chad Patterson sold 777 shares of DexCom stock in a transaction on Monday, May 9th. The shares were sold at an average price of $342.77, for a total value of $266,332.29. Following the transaction, the executive vice president now owns 13,675 shares in the company, valued at approximately $4,687,379.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Steven Robert Pacelli sold 1,000 shares of DexCom stock in a transaction on Thursday, June 23rd. The stock was sold at an average price of $72.55, for a total transaction of $72,550.00. Following the completion of the transaction, the director now owns 139,700 shares in the company, valued at approximately $10,135,235. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,877 shares of company stock valued at $703,892. 0.41% of the stock is owned by company insiders.

Shares of NASDAQ:DXCM opened at $81.24 on Monday. The firm has a fifty day moving average of $86.57 and a two-hundred day moving average of $104.00. The firm has a market capitalization of $31.89 billion, a P/E ratio of 156.99, a price-to-earnings-growth ratio of 3.48 and a beta of 1.03. DexCom, Inc. has a 12-month low of $66.89 and a 12-month high of $164.86. The company has a quick ratio of 4.79, a current ratio of 5.27 and a debt-to-equity ratio of 0.90.

DexCom (NASDAQ:DXCMGet Rating) last released its quarterly earnings data on Thursday, April 28th. The medical device company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.04). DexCom had a net margin of 8.23% and a return on equity of 12.42%. The business had revenue of $628.80 million during the quarter, compared to analyst estimates of $623.97 million. During the same period in the previous year, the firm posted $0.08 EPS. The firm’s revenue for the quarter was up 24.5% on a year-over-year basis. Equities research analysts expect that DexCom, Inc. will post 0.75 earnings per share for the current fiscal year.

DexCom Company Profile (Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Featured Articles

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for DexCom and related companies with MarketBeat.com’s FREE daily email newsletter.

Source: defenseworld.net

About the author

Amanda

Hi there, I am Amanda and I work as an editor at impactinvesting.ai;  if you are interested in my services, please reach me at amanda.impactinvesting.ai

Leave a Comment